Author: OurCrowd

[TechSee in PR Newswire] MEO and TechSee win “Technology of the Year” at 2026 Excellence in Customer Service Awards for Visual AI Innovation

Apr 23, 2026 |

LISBON, Portugal, April 23, 2026 /PRNewswire/ — MEO, part of the Altice Group and one of Portugal’s leading telecommunications providers and TechSee, have been named the Overall Winner in the “Technology of the Year (Product)” category at the 2026 Excellence in Customer Service Awards, presented by the Business Intelligence Group. The recognition highlights MEO’s end-to-end Visual AI customer service journey developed in partnership with TechSee. Read...

Read More

[Clinch in PR Newswire] Clinch brings AI-driven creative personalization to pause ads through OpenGlass partnership

Apr 23, 2026 |

NEW YORK, April 23, 2026 /PRNewswire/ — Clinch, the operating system for autonomous advertising, and OpenGlass, the first SSP built for advanced CTV advertising, today announced that Clinch’s ad-serving tags have been certified to run within OpenGlass’s Advanced CTV Formats, beginning with pause ads, across publishers like Paramount, Tubi, TiVo, DirecTV, Sling/Dish, Philo, Xumo, and Plex. The certification gives advertisers a single operational path to deliver personalized, data-driven creative via one of streaming’s highest-attention formats. Read more...

Read More

[Classiq in Globe Newswire] Classiq Certifies Expert-Level Quantum AI Agents for Real-World Applications

Apr 23, 2026 |

BOSTON, April 23, 2026 (GLOBE NEWSWIRE) — Classiq, the leading quantum computing software company, today announced a significant acceleration for quantum software development: a new AI agentic layer that enables users to move from natural-language intent to structured, executable quantum applications, powered by a first-generation, expert-level quantum agent. Read More...

Read More

[Alpha Tau in Globe Newswire] Alpha Tau announces FDA Approval of IDE supplement to expand Alpha DaRT® IMPACT trial to patients with pancreatic cancer receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

Apr 23, 2026 |

JERUSALEM, April 23, 2026 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that the FDA has approved an Investigational Device Exemption (IDE) supplement to its U.S. multi-center pancreatic cancer pilot study, known as IMPACT (Intratumoral Pancreatic Alpha Combination Trial), evaluating the safety, feasibility, and efficacy of Alpha DaRT in combination with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma. Read...

Read More

[Alpha Tau in Alpha Tau] Alpha Tau successfully treats first pancreatic cancer patient in Europe with Alpha Dart® in French multicenter ACAPELLA clinical trial

Apr 23, 2026 |

Jerusalem, April 23, 2026 – Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the successful treatment of the first patient in ACAPELLA (Alpha DaRT for CAncer of the PancrEas in Locally advanced Adenocarcinoma), the Company’s European multicenter clinical trial evaluating Alpha DaRT combined with capecitabine for patients with inoperable locally advanced pancreatic ductal adenocarcinoma (LAPC) who have completed first-line mFOLFIRINOX chemotherapy. Read...

Read More